Rivaroxaban in acute coronary syndromes: too soon to know?
Gurm
Hitinder S
HS
University of Michigan Cardiovascular Center, Ann Arbor, MI 48109-5852, USA.
Eagle
Kim
K
D054058:Acute Coronary Syndrome / Q000401:mortality / Q000517:prevention & control*; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000069552:Rivaroxaban; D055502:Secondary Prevention / Q000379:methods; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban